BIAFW BIOAFFINITY TECHNOLOGIES INC C/WTS 12/08/2027 (TO PUR COM)
- 0.300
- -0.104-25.69%
8-K: Current report
S-1: General form for registration of securities under the Securities Act of 1933
DEF 14A: Definitive information statements
8-K: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
PRE 14A: Preliminary proxy statements relating to merger or acquisition
8-K: Securities Purchase Agreement
8-K: bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
8-K: bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
8-K: Poll Results of 2024 Extraordinary General Meeting
S-1: General form for registration of securities under the Securities Act of 1933
DEF 14A: Definitive information statements
PRE 14A: Preliminary proxy statements relating to merger or acquisition
8-K: Appointment of new Chief Financial Officer
8-K: bioAffinity Technologies Announces Pricing of Registered Direct Offering and Concurrent Private Placement and Warrant Inducement for Aggregate Gross Proceeds of $1.75 Million
8-K: 2024 Second Quarter Financial Results
S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
8-K: Poll Results of 2024 Stockholders Meeting
8-K: First Quarter 2024 Financial Results
BIOAFFINITY TECHNOLOGIES INC C/WTS 12/08/2027 (TO PUR COM) | DEF 14A: Definitive information statements
BIOAFFINITY TECHNOLOGIES INC C/WTS 12/08/2027 (TO PUR COM) | DEFA14A: Others